Clinical activity was shown for the cedi/ola combination in heavily pretreated, non-gBRCAm, platinum-resistant patients with ovarian cancer despite failing to meet the target ORR of 20%, highlighting a need for further biomarker studies.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2022) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: